- Home
- ABUS vs KALV Comparison
ABUS vs KALV Comparison
Compare ABUS & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- KALV
- Stock Information
- Founded
- ABUS 2005
- KALV N/A
- Country
- ABUS United States
- KALV United States
- Employees
- ABUS N/A
- KALV N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- ABUS Health Care
- KALV Health Care
- Exchange
- ABUS Nasdaq
- KALV Nasdaq
- Market Cap
- ABUS 711.2M
- KALV 796.4M
- IPO Year
- ABUS N/A
- KALV N/A
- Fundamental
- Price
- ABUS $4.46
- KALV $11.36
- Analyst Decision
- ABUS Strong Buy
- KALV Strong Buy
- Analyst Count
- ABUS 2
- KALV 8
- Target Price
- ABUS $5.00
- KALV $26.43
- AVG Volume (30 Days)
- ABUS 930.7K
- KALV 1.2M
- Earning Date
- ABUS 11-10-2025
- KALV 12-04-2025
- Dividend Yield
- ABUS N/A
- KALV N/A
- EPS Growth
- ABUS N/A
- KALV N/A
- EPS
- ABUS N/A
- KALV N/A
- Revenue
- ABUS $15,416,000.00
- KALV $1,426,000.00
- Revenue This Year
- ABUS $138.02
- KALV N/A
- Revenue Next Year
- ABUS N/A
- KALV $215.46
- P/E Ratio
- ABUS N/A
- KALV N/A
- Revenue Growth
- ABUS 53.23
- KALV N/A
- 52 Week Low
- ABUS $2.71
- KALV $7.30
- 52 Week High
- ABUS $5.10
- KALV $17.28
- Technical
- Relative Strength Index (RSI)
- ABUS 54.42
- KALV 44.42
- Support Level
- ABUS $4.26
- KALV $10.84
- Resistance Level
- ABUS $4.61
- KALV $11.65
- Average True Range (ATR)
- ABUS 0.20
- KALV 0.58
- MACD
- ABUS -0.01
- KALV 0.04
- Stochastic Oscillator
- ABUS 65.45
- KALV 41.22
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.